Background and Aim: Worldwide, 1,470,900 women are diagnosed yearly with a gynecological malignancy (21,000 in the UK). Some patients treated with pelvic radiotherapy develop chronic changes in their bowel function. This systematic review summarizes current research on the impact of cancer treatment on the gut and vaginal microbiome in women with a gynecological malignancy. Methods: The Preferred reporting Items for Systematic Reviews and Meta-analyses guidelines for systematic reviews were used to ensure transparent and complete reporting. Quantitative studies exploring the gut or vaginal microbiome in this patient cohort were included. Animal studies were excluded. There were no language restrictions. Results: No studies examined the possible effects of surgery or chemotherapy for gynecological cancers on the gut or vaginal microbiome. Three prospective cohort studies were identified using sequencing of changes in the gut microbiome reporting on a total of 23 women treated for gynecological cancer. All studies included patients treated with radiotherapy with a dosage ranging from 43.0 to 54.0 Gy. Two studies assessed gastrointestinal toxicity formally; 8 women (57%) developed grade 2 or 3 diarrhea during radiotherapy. The outcomes suggest a correlation between changes in the intestinal microbiome and receiving radiotherapy and showed a decrease in abundance and diversity of the intestinal bacterial species. Before radiotherapy, those who developed diarrhea had an increased abundance of Bacteroides, Dialister, and Veillonella (P G 0.01), and a decreased abundance of Clostridium XI and XVIII, Faecalibacterium, Oscillibacter, Parabacteroides, Prevotella, and unclassified bacteria (P G 0.05). Conclusion: The limited evidence to date implies that larger studies including both the vaginal and gut microbiome in women treated for a gynecological malignancy are warranted to explore the impact of cancer treatments on the microbiome and its relation to developing long-term gastrointestinal toxicity. This may lead to new avenues to stratify those at risk and explore personalized treatment options and prevention of gastrointestinal consequences of cancer treatments.
M ore than 14 million people worldwide are diagnosed with a new cancer annually. 1 Yearly, 1,470,900 women are diagnosed with gynecological malignancy (21,000 in the UK).
Treatment for gynecological cancers includes surgery, radiotherapy, and chemotherapy. Radiation delivered by external beam radiotherapy or brachytherapy frequently causes acute gastrointestinal toxicity, and up to half of all patients experience chronic change in bowel function. Few data are available with regard to long-term gastrointestinal toxicity after surgery and chemotherapy. 2 Gastrointestinal symptoms after cancer treatment may include diarrhea, abdominal pain, bowel frequency, fecal incontinence, borborygmi, tenesmus, and flatulence. 3 These symptoms cause fatigue and affect well-being, relationships, and socioeconomic status. The impact of these symptoms on quality of life and daily activities is often not assessed or addressed.
Although progress has been made in defining optimal management of chronic changes in bowel function after cancer treatment, 3 the ability to predict and risk-stratify in advance those who might develop serious problems as a result of treatment would herald a major advance in outcomes for cancer survivors.
Mechanisms by which gastrointestinal symptoms occur after cancer treatment are starting to be understood, and personal parameters that change the risk of adverse effects for individuals are identified. Body mass index, concomitant chemotherapy, use of a statin or angiotensin-converting enzyme inhibitor, diabetes mellitus, connective tissue disorders, or HIV disease all alter risk of long-term consequences. 4 The gut microbiome, however, may be the key to understanding gastrointestinal toxicity during and after cancer treatment. 5 The bacteria within the gastrointestinal tract contribute to health, mood, and general well-being by regulating major epithelial and immune functions and feedback to the brain via the vagus nerve and hormone secretion particularly about energy uptake. 6, 7 In health, microbiomes in the gut and vagina are separated from the host by a multilevel barrier supported by immune cells neutralizing pathogens. Failure of this barrier either in the gut or vaginal epithelia can cause low-grade chronic inflammation leading to cardiovascular disease, inflammatory bowel disease, and cancer. 7Y9 Cancer itself can cause inflammation leading to dysbiosis, creating a positive feedback loop promoting disease. 8, 10 The gastrointestinal microbiome is an ecosystem of up to 1000 bacterial species in any one individual. 11 In health, 90% of the total gastrointestinal microbiome is populated by 5 major bacterial phyla: Firmicutes, Bacteroidetes, Actinobacteria, Proteobacteria, and Fusobacteria. 9 The composition within individuals remains stable for 60% of species over time. 12, 13 The gut microbiome has a high diversity in healthy people. There is a clear link between gut microbiotic composition and pathological states, for example, inflammatory bowel disease. 5, 14, 15 The composition of the gut microbiome is less diverse in obese people who have a higher proportion of Firmicutes and fewer Bacteriodes. 16, 17 There is reduced diversity in people with diarrhea after pelvic radiotherapy. 18 A healthy vaginal microbiome is typically populated by aerobic members of the Firmicutes phylum, dominated by Lactobacillus crispatus, Lactobacillus gasseri, Lactobacillus iners, and Lactobacillus jensenii. 19 Alterations in the vaginal microbiome lead to conditions such as bacterial vaginosis, where vaginal lactobacilli are reduced and replaced by anaerobic bacteria. 20 Research into the vaginal and cervical microbiome was initially promoted by the desire to prevent and treat radiation fever, which was believed to be due to ascending infection by pathogenic vaginal bacteria and could result in delays delivering radiotherapy, dose reduction, and poorer treatment outcomes. 21Y29 The notion that radiotherapy sterilized the cervix was dispelled by studies analyzing aerobic and anaerobic cultures.
21Y29 These studies, however, differed in their conclusions as to the role of the genital tract microbiome in oncogenesis, whether in the presence of gynecological malignancy it differed from that in health and the significance of changing bacterial composition during and after treatment.
Febrile morbidity in women receiving pelvic radiotherapy is no longer a concern. Prophylactic use of antibiotics before gynecological procedures makes risk of infection after biopsies or surgical intervention less common. 30 However, even short courses of antibiotics result in reduction in gut microbiota diversity lasting 6 months to 4 years. 31 The use of antibiotics and its implications for maintaining human health and resilience to disease need to be acknowledged. 32 Recent efforts have focused on how the vaginal microbiome impacts on gynecological malignancy development. Women with vaginal dysbiosis have a higher risk of developing cervical preneoplastic changes over time (odds ratio, 2.00; 95% confidence interval, 1.31Y3.05), whereas women with Candidiasis do not (odds ratio, 0.42; 95% confidence interval, 0.11Y1.70).
33Y38
Disturbance of the vaginal flora increases the risk of acquiring oncogenic human papillomavirus (HPV), 33, 38 which plays a causal role in the development of precancerous cervical intraepithelial neoplasia and invasive cervical cancer. 34, 38 Although HPV infection is common in sexually active women and may be indicative of sexual behavior predisposing to HPV, most infections are transient. Only a small proportion of infected women develop clinically significant preinvasive lesions or invasive malignant disease. The HIV and HPV status is now routinely tested in women with cervical cancer. 9, 39 The gut microbiome produces estradiol, which may promote oestrogen-driven malignancies such as endometrial cancer. 40 The intestinal and vaginal microbiome also plays a significant role in response to oncological treatments and long-term toxicity from those treatments. 41, 42 The number of people living with and beyond cancer has tripled over the last decade, and reducing long-term toxicity is a priority. 43 
Analyzing the Gastrointestinal and Genital Tract Microbiome
Older methods relied on bacterial culture using gram staining, gas-liquid chromatography, or biochemical tests. These approaches are limited by the inability to culture all bacterial species and do not detect changes in bacterial functions.
Modern research uses next-generation sequencing methodologies (DNA, rDNA, and rRNA) and metagenomics to analyze the DNA of the entire microbial community and to understand how radiotherapy possibly induces changes in microbial composition. However, the virome is rarely included, 15, 44 and these techniques are complex, expensive, and mostly do not measure changes in microbial function, which may be as important as changes in composition.
Alternative options for analyzing the gut microbiome include examining gases produced by the metabolites of the gut microorganisms, volatile organic compounds (VOCs). Volatile organic compounds are organic chemicals that derive from biological samples such as breath, feces, sweat, urine, or vaginal fluid and are gas-phase biomarkers reflecting individuals' metabolic state. 45Y47 The gold standard for analyzing VOCs is gas chromatography/mass spectrometry. However, this technique is expensive and specialized and is not a viable option for day-to-day clinical practice. 47 Two alternative techniques can analyze VOCs to draw a unique olfactory signature: electronic sensing (e-nose) or high field asymmetric ion mobility spectrometry. These detect specific chemical compounds indicating changes in gut microbiome metabolism involved in fermentation processes. 47 This review aims to summarize existing research using modern analysis methodologies on the impact of cancer treatment (surgery, chemotherapy, and radiotherapy) on the gut and vaginal microbiome in women with a gynecological malignancy.
METHODS

Literature Identification
This systematic review used the Preferred reporting Items for Systematic Reviews and Meta-analyses guidelines to ensure transparent and complete reporting (Appendix 1, http://links.lww.com/IGC/A485). 48 The review protocol was registered on the International PROSPERO review database: PROSPERO 2016:CRD42016047121 http://www.crd.york. ac.uk/PROSPERO/display_record.asp?ID=CRD42016047121. (Fig. 1) .
Search Strategy
To ensure that the search was comprehensive and studies had not been missed or wrongly excluded, the unpublished and gray literature, general search engines, and reference lists of included papers were checked. Contact was made with the authors of the articles when further information was required. A second reviewer (C.N.) independently analyzed the articles.
The main search terms included gynecological cancer, gynecological malignancy, gynecological cancer, gynecological malignancy, cervix cancer, endometrial cancer, uterine cancer, gut microbiome, intestinal microbiome, vaginal microbiome, vaginal swabs, surgery, chemotherapy, radiotherapy, pelvic radiotherapy, chemoradiation, sequencing, and VOC analysis. Appendix 2, http://links.lww.com/IGC/A485 presents an example of the full electronic search strategy for the OVID \ database.
Types of Studies Included
Quantitative studies exploring the gut or vaginal microbiome in women treated for a gynecological malignancy were included. There were no language restrictions. Animal studies, case reports or studies including single subjects, expert opinions, and consensus statements were excluded. Because of recent advances in treatment (specifically radiotherapy) and new techniques to analyze the microbiome, studies with older conventional culturing techniques were excluded.
As a systematic review protocol assessing the impact of probiotics for the prevention or treatment of chemotherapy-or radiotherapy-related diarrhea in patients with cancer has been published by the Cochrane collaboration, 49 studies including the use of pre-or probiotics as an intervention were excluded.
Inclusion criteria were defined using the following components: patient population (P)Vwomen treated for a gynecological malignancy; exposure of interest (I)Vcancer treatment: surgery, chemotherapy, or radiotherapy; comparator (C)Vbefore and after treatment for gynecological cancer; outcome (O)Vthe change in the gut or vaginal microbiome after treatment for gynecological cancer; and the study designs (S) of interestVrandomized controlled trials (RCTs), prospective observational cohort studies, and retrospective studies.
RESULTS
No studies were identified examining the possible effects of surgery for gynecological cancers on the gut microbiome or charting changes in the gut microbiome of women treated with chemotherapy alone. One study included 7 women who received concomitant chemoradiation. 50 Analysis of gut microbiotic profiles showed that the number of operational and taxonomic units (OTUs) and the richness in bacterial species decreased. However, the impact of chemotherapy alone on the gut microbiome remains unclear.
No studies have examined changes in the vaginal microbiome during treatment for gynecological malignancies and how this may affect long-term toxicity.
No studies were identified using VOC analysis methods examining the metabolites of gut or vaginal microbiome involving women treated for gynecological tumors.
A total of 5 studies and 2 abstracts were identified using sequencing to analyze the gut microbiome during treatment with pelvic radiotherapy. One study was excluded, 51 as it described a single case of a woman treated for ovarian cancer in a cohort of 19 patients receiving chemotherapy for a range of malignancies. Both abstracts were excluded, as 1 related to a full publication ( Table 1, Table 2 ) and 1 described the cohort as ''cancer patients treated with pelvic radiotherapy.'' Contact with the authors revealed this study only included men treated for prostate cancer. 52 The remaining studies were included and critically appraised using the Critical Appraisal Skills Programme (CASP) study checklist for observational cohort studies (Tables 1). 53 They reported on a total of 23 women with gynecological cancer: endometrial cancer (n = 7) and cervical cancer (n = 16). One study included only women with a gynecological cancer. 50 The 2 other studies also included patients receiving treatment for gastrointestinal cancers. 18, 54 It was not possible to identify outcomes for the women with gynecological cancer separately. Before radiotherapy, compared with patients who did not develop diarrhea, those who did had increased abundance of Bacteroides, Dialister, and Veillonella, and decreased abundance of Clostridium XI and XVIII, Faecalibacterium, Oscillibacter, Parabacteroides, Prevotella, and unclassified (genus: others)
Outcomes of Included Studies
All 3 studies were prospective cohort studies and included patients treated with radiotherapy dose ranging from 43.0 to 54.0 Gy but did not provide specific information about radiotherapy fields, the use of boosts, or brachytherapy, making comparison difficult. Although all studies acknowledge that radiotherapy may result in toxicity, 1 study did not report gastrointestinal toxicity. 50 In the other studies, the Common Toxicity Criteria (CTC) version 2.0 18 and the Common terminology Criteria for Adverse Events (CTCAE) version 3.0 54 assessed bowel function. Where stool consistency was reported, 8 (57%) women developed grade 2 or 3 diarrhea during radiotherapy. One study also assessed levels of fatigue using the Multidimensional Fatigue Inventory-20 general fatigue score and added measurement of biochemical markers of inflammation from blood samples. 54 These studies suggest a correlation between changes in the intestinal microbiome and radiotherapy. All studies showed decrease in abundance and diversity of the intestinal bacterial species. One study identified 10% decrease in firmicutes (P = 0.09), 3% increase in fusobacteria (P = 0.05), and 9.9% in unclassified bacteria (P = 0.04). 50 An increase in unspecified bacterial species was seen in those with diarrhea, but patients without diarrhea maintained their bacterial profiles. 18, 54 Before radiotherapy, those who developed diarrhea compared with those who did not, had increased abundance of Bacteroides, Dialister, and Veillonella (P G 0.01), and a decrease in Clostridium XI and XVIII, Faecalibacterium, Oscillibacter, Parabacteroides, Prevotella, and unclassified bacteria (P G 0.05). 54 Level of evidence is classified as B. 55 The quality of the studies had CASP scores of 6/11 and 7/11 (Table 2) . 18, 50, 54 
DISCUSSION
This review highlights the lack of studies mapping changes in the gut or vaginal microbiomes in women with gynecological malignancies before, during, and after treatment.
In all identified studies, the rationale for the study was clearly outlined, namely, that radiotherapy can result in serious toxicity and the underlying cause remains unknown. Mainly opinion papers and reviews are used in the background sections of these papers. These studies are essentially feasibility studies that strengthen the rationale for further research. This is especially relevant in view of the emerging studies evaluating probiotics to reduce gastrointestinal toxicity. 56Y58 These report varying success rates perhaps due to the gap in understanding the impact of multimodal therapies for gynecological malignancies on the microbiome. This missing information prevents us offering treatment options targeted to the individual patient.
Two studies included multimodal cancer therapies that draw attention to the complexity in determining how different treatment interact pathophysiologically with the microbiome in gynecological malignancy. Although receiving chemotherapy was an exclusion criterion for 2 studies, 18, 54 another 50 included 7 women receiving a variety of chemotherapeutic agents.
Only 2 studies assessed acute gastrointestinal toxicity formally, measuring diarrhea. There was no difference in assessing diarrhea between the tools used. 59 As the last follow-up, time point was 2 months after radiotherapy; longer term gastrointestinal toxicity, which manifests months or years after treatment, 3 was not assessed and future research needs to incorporate much longer follow-up.
Limitations of the Studies
These were single-centered studies. No information regarding how many patients were treated in each center, how many patients were eligible, how eligible patients were selected, or the time scale for recruitment was provided. This may have introduced selection bias. The researchers did not specify guidelines used to stop recruitment. This raises concerns about equity for potential study participants. Information about catchment areas and number of patients treated could have provided additional insight into whether the sample population is representative for the wider population. All studies used healthy volunteers as controls, but none described the selection methods or demographic information.
In all studies, no missing data were reported although 1 study mentions a dropout rate of 45%. Reporting bias may potentially result if participants only included if they were able to provide all data for inclusion of the final analysis. The inclusion of different tumor types and mixed-sex cohorts complicates interpretation of the results, as individual patient outcomes could not be separated for analysis. In addition, all 3 studies were set in different countries and lacked information about other possible confounding factors such as diet, body mass index, medications affecting the gut microbiome or gastrointestinal function, treatment with previous surgery or chemotherapy, and comorbid factors.
The discussion sections addressed a number of key areas; the researchers acknowledge the limitations of 16S rRNA sequencing as not all bacterial species can be adequately identified and support future studies with larger cohorts. Two studies excluded patients treated with antibiotics before radiotherapy, whereas all studies excluded those receiving antibiotics during treatment or the use of corticosteroids and immunosuppressants. Although the long-term impact of the use of antibiotics resulting in sustained reductions in gut microbial diversity has been acknowledged, 31 excluding those patients does not reflect clinical oncological management.
Research in the emerging field of the microbiome is currently biased toward the gut microbiome, and little is known about interactions with the vaginal microbiome. The viromes and fungal populations have been neglected and may be important. Several studies have examined the vaginal microbiome of women at different stages of malignancy compared with that of women without cancer.
34Y39,60,61 However, no studies reported long-term sequential follow-up data to determine the role of changes in the vaginal microbiome during progression from precancerous lesions to cancer.
The studies to date mostly use sequencing and did not include metabonomic analysis techniques. The clinical relevance of sequencing used in isolation may be limited. One 45 No studies were found using VOC analysis to describe the vaginal microbiome in women with gynecological cancer nor how treatment such as surgery, chemotherapy, and pelvic radiotherapy may impact on the vaginal microbiome of these women. Inclusion of metabonomic analysis techniques offers additional avenues to develop risk-stratification pathways and targeted treatment options.
Limitations of the Review
This review was limited to prospective cohort studies assessing the gut and vaginal microbiome of women treated for a gynecological malignancy. No animal studies were included. In view of recent advances in novel, more targeted radiotherapy techniques and technology available to analyze the microbiome, the findings of older studies need to be interpreted cautiously. Because of the small number of studies found and the heterogeneity in study subjects in terms of treatment modalities and reporting methods, meta-analysis was not performed. Registration of this review on the International PROSPERO database reduced the risk of multiple reviews addressing the same question and limited publication bias and provided transparency for updating the review in the future. 48 
Implications for Future Research
The limited evidence implies that the role of the vaginal and gut microbiome in women treated for a gynecological malignancy is relevant and requires further study.
CONCLUSION
The outcomes of these studies support the hypothesis that radiotherapy changes the intestinal microbiome in patients with a decrease in abundance and diversity of the intestinal bacterial species.
Further characterization of differences and changes in the genital and gastrointestinal microbiome and intestinal function before and after treatment could improve understanding of why some patients develop more severe toxicity and why others remain symptom free. This may lead to new avenues to stratify those at risk and explore personalized treatment options and prevention of consequences of cancer treatments.
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